<DOC>
	<DOCNO>NCT02524639</DOCNO>
	<brief_summary>The purpose pilot study generate data ass feasibility study design/procedures formal sample size estimation large multicenter study efficacy safety sirolimus infant medically-unresponsive congenital hyperinsulinism ( HI ) due inactivate mutation adenosine triphosphate-sensitive potassium ( KATP ) channel .</brief_summary>
	<brief_title>Sirolimus Treatment Hyperinsulinism</brief_title>
	<detailed_description>Treatment option child diffuse adenosine triphosphate-sensitive potassium ( KATP ) channel hyperinsulinism ( KATPHI ) limit require near-total pancreatectomy control hypoglycemia . However , least 40 % child continue persistent hypoglycemia surgery long-term outcome complicate development diabetes . There evidence suggest mammalian target rapamycin ( mTOR ) inhibitor useful control hypoglycemia hyperinsulinemic hypoglycemia . But adapt standard therapy child hyperinsulinism , carefully control study efficacy safety sirolimus hyperinsulinism clearly need . Sirolimus mTOR inhibitor , FDA-approved prophylaxis organ rejection patient age 13 year old receive kidney transplantation . This open label pilot study assess effect , safety tolerability sirolimus infant diazoxide-unresponsive HI due mutation gene encode KATP channel . Subjects treat sirolimus 6 week .</detailed_description>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Males females age â‰¥14 day 12 month . 2 . Confirmed diagnosis hyperinsulinism . 3 . Mutation analysis result demonstrate biallelic mutation either ABCC8 KCNJ11 . 4 . Failure respond maximal dose diazoxide ( 15 mg/kg/day ) , diazoxide indicate . 1 . Unable wean intravenous dextrose least 3 day diazoxide therapy and/or 2 . Persistent hypoglycemia least 3 day diazoxide therapy 5 . High glucose infusion rate requirement ( great equal 10 mg/kg/min ) . 6 . Parental/guardian permission ( informed consent ) . 1 . Infants suspect confirmed focal hyperinsulinism candidate surgical resection 2 . Current therapy diazoxide . Subjects may eligible participation 48 hr discontinuation diazoxide . 3 . Laboratory abnormality indicate clinically significant hematologic , hepatobiliary , renal disease : 1 . AST/SGOT &gt; 2.5 time upper limit normal 2 . ALT/SGPT &gt; 2.5 time upper limit normal 3 . Total bilirubin &gt; 2.5 time upper limit normal 4 . Hemoglobin &lt; 9 gm/dL 5 . White blood cell count &lt; 3,000/ mm3 6 . Platelet count &lt; 100,000/mm3 7 . Creatinine &gt; 2.5 time upper limit normal 4 . Evidence active infection . 5 . Evidence cardiac respiratory failure . 6 . Known immune deficiency . 7 . Preterm ( &lt; 37 week gestation birth ) . 8 . Treatment immunosuppressant . 9 . Treatment drug know interact significantly sirolimus ( strong inducer strong inhibitor CYP3A4 Pgp risk category D X ) include : Cyclosporine , clozapine , conivaptan , crizotinib , dabrafenib , dipyrone , boceprevir , echinacea , efavirenz , enzalutamide , fluconazole , fosphenytoin , fusidic acid , idelalisib , leflunomide , lomitapide , mifepristone , mitotane , natalizumab , nelfinavir , phenytoin , pimecrolimus , pimozide , posaconazole , roflumilast , St Johns Wort , stiripentol , tacrolimus , telaprevir , tofacitinib , rifampin , rifabutin , ketoconazole , voriconazole , itraconazole , erythromycin , telithromycin , clarithromycin 10 . Any investigational drug use within 5 halflives drug prior initiation therapy . Subjects participate investigational drug study eligible participate 5 halflives last dose investigational agent recover acute investigational agent associate toxicity 11 . History surgical procedure within 8 week enrollment . 12 . Parents/guardians subject , opinion Investigator , may noncompliant study schedule procedure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>